Neumora Therapeutics Receives Nasdaq Bid Price Deficiency Notice
The company has until April 26, 2027, to regain compliance with the $1.00 minimum bid price requirement.
Neumora Therapeutics NMRA
Neumora Therapeutics, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)
$0.37-5.36%close on Oct. 30, 2026 · volume 1.1M · Yahoo Finance
Price, last 49 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Aug. 21, 2026 | Daljit Singh Aurora See Remarks | Sold | 20,553 | $1.59 | $32,780 |
| Aug. 21, 2026 | Daljit Singh Aurora See Remarks · indirect | Sold | 21,055 | $1.60 | $33,600 |
| Aug. 20, 2026 | Daljit Singh Aurora See Remarks | Sold | 67,741 | $1.51 | $102,587 |
| Aug. 20, 2026 | Daljit Singh Aurora See Remarks · indirect | Sold | 66,711 | $1.51 | $101,000 |
| Aug. 19, 2026 | Daljit Singh Aurora See Remarks | Sold | 31,000 | $1.65 | $51,029 |
| Aug. 19, 2026 | Daljit Singh Aurora See Remarks · indirect | Sold | 30,918 | $1.65 | $50,888 |
| Aug. 18, 2026 | Daljit Singh Aurora See Remarks | Sold | 34,162 | $1.58 | $54,137 |
| Aug. 18, 2026 | Daljit Singh Aurora See Remarks · indirect | Sold | 34,987 | $1.59 | $55,486 |
| Aug. 17, 2026 | Daljit Singh Aurora See Remarks | Sold | 91,690 | $1.50 $1.49-$1.51 | $137,352 |
| Aug. 17, 2026 | Daljit Singh Aurora See Remarks · indirect | Sold | 55,016 | $1.50 | $82,783 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 10 →Delisting notice / failure to meet listing standard
AI summary, unreviewedNeumora Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice, Has Until April 26, 2027 to Regain Compliance